New Advances in the Treatment of Chronic Myelogenous Leukemia CME/CE

Susan O'Brien, MD Author Information and Disclosures

Release Date: May 23, 2008; Valid for credit through May 23, 2009

Credits Available
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.8 ANCC contact hours

A presentation from the NCCN 13th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida. This activity was designed to be completed within approximately 45 minutes.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 National Comprehensive Cancer Network
Novartis Oncology
Learning Objectives
Following this activity, participants should be able to:
  • Identify recent developments in treatment options for chronic myelogenous leukemia (CML)
  • Explain how these developments can help patients with CML
  • Describe the development of imatinib resistance and management strategies for patients who develop resistance
Author Disclosures
Susan O'Brien, MD
Professor of Medicine, Department of Leukemia; University of Texas M. D. Anderson Cancer Center; Houston, Texas

Disclosure: Dr. O'Brien has disclosed that she has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the activity. She has received grant/research support from Berlex Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; and Novartis Pharmaceuticals Corporation.

Dr. O'Brien has indicated that her presentation will not include discussion of investigational or unlabeled uses of commercial products.
 
National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.

NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

More Activities from NCCN

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.